Fennec Pharmaceuticals
FENC
31 hedge funds and large institutions have $92.1M invested in Fennec Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 10 reducing their positions, and 4 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
46% more capital invested
Capital invested by funds: $63.2M → $92.1M (+$28.9M)
11% more funds holding
Funds holding: 28 → 31 (+3)
0.28% more ownership
Funds ownership: 43.32% → 43.6% (+0.28%)
43% less call options, than puts
Call options by funds: $2.97M | Put options by funds: $5.19M
60% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 10
Top Buyers
| 1 |
EI
EAM Investors
Solana Beach,
California
|
+$1.21M |
| 2 |
TA
Tamarack Advisers
Carlsbad,
California
|
+$1.2M |
| 3 |
JG
Jefferies Group
New York
|
+$237K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$108K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$102K |
Top Sellers
| 1 |
DCM
DG Capital Management
New York
|
-$1.41M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$337K |
| 3 |
SCM
Solas Capital Management
Darien,
Connecticut
|
-$291K |
| 4 |
6CM
683 Capital Management
New York
|
-$278K |
| 5 |
Goldman Sachs
New York
|
-$56K |
FENC Hedge Fund Activity: Q3 2022 in Review
31 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Fennec Pharmaceuticals (FENC) for Q3 2022, worth a combined $92.1M — up 46% from $63.2M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new FENC positions and 4 closed out — a net gain of 3 holders — while 4 added to existing stakes and 10 trimmed.
The largest buyer was EAM Investors, opening a new position worth an estimated $1.21M. The largest seller was DG Capital Management, cutting an estimated $1.41M.
- 31 institutional investors held Fennec Pharmaceuticals (FENC) as of Q3 2022, up from 28 in Q2 2022.
- Funds reported $92.1M of Fennec Pharmaceuticals stock for Q3 2022, up 46% quarter-over-quarter.
- 7 funds opened new Fennec Pharmaceuticals positions in Q3 2022 and 4 closed out, a net change of +3 holders.
- The largest Fennec Pharmaceuticals buyer in Q3 2022 was EAM Investors, an estimated $1.21M added.
- The largest Fennec Pharmaceuticals seller in Q3 2022 was DG Capital Management, an estimated $1.41M sold.
Based on aggregated 13F filings for Q3 2022.